<SEC-DOCUMENT>0001144204-15-025170.txt : 20150427
<SEC-HEADER>0001144204-15-025170.hdr.sgml : 20150427
<ACCEPTANCE-DATETIME>20150427144344
ACCESSION NUMBER:		0001144204-15-025170
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20150424
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150427
DATE AS OF CHANGE:		20150427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-25809
		FILM NUMBER:		15794795

	BUSINESS ADDRESS:	
		STREET 1:		450 NORTH BRAND BLVD.,
		STREET 2:		SUITE 600
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203
		BUSINESS PHONE:		818-396-8050

	MAIL ADDRESS:	
		STREET 1:		700 N. BRAND BLVD.,
		STREET 2:		SUITE 220
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v408340_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
April 24, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APOLLO MEDICAL HOLDINGS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Delaware</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">000-25809</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>46-3837784</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State or Other Jurisdiction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission File</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">of Incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">700 N. Brand Blvd., Suite 220, Glendale,
CA 91203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(818) 396-8050</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.03 Material Modification to Rights of Security Holders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent required by Item 3.03 of Form 8-K, the information
contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 24, 2015, Apollo Medical Holdings, Inc. (the &ldquo;Company&rdquo;)
filed an Amendment to the Company&rsquo;s Restated Certificate of Incorporation (the &ldquo;Certificate of Amendment&rdquo;) with
the Secretary of State of the State of Delaware to effect a one-for-ten reverse stock split of the Company&rsquo;s common stock
(the &ldquo;Reverse Stock Split&rdquo;). The Certificate of Amendment provides that the Reverse Stock Split became effective as
of the date of the filing with the Secretary of State of the State of Delaware (the &ldquo;Effective Time&rdquo;), at which time
every ten shares of the Company&rsquo;s issued and outstanding common stock were automatically combined into one issued and outstanding
share of the Company&rsquo;s common stock, without any change in the par value per share. The number of authorized, but unissued,
shares is not affected. No fractional shares will be issued following the Reverse Stock Split and the Company will pay cash in
lieu of any fractional shares resulting from the Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Certificate of Amendment is attached as Exhibit
3.1 hereto and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the press release announcing the Reverse Stock Split
is attached as Exhibit 99.1 hereto and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.1</TD><TD STYLE="text-align: justify">Certificate of Amendment to the Restated Certificate of
Incorporation of Apollo Medical Holdings, Inc.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">99.1</TD><TD STYLE="text-align: justify">Press release dated April 24, 2015 announcing the Reverse
Stock Split</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>APOLLO MEDICAL HOLDINGS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: April 27, 2015</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:&nbsp;</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Warren Hosseinion</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Warren Hosseinion</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:&nbsp;&nbsp;&nbsp;&nbsp; Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>v408340_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 3.1</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CERTIFICATE
OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>RESTATED CERTIFICATE
OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>APOLLO MEDICAL
HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">Apollo Medical
Holdings, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware
(the &ldquo;<U>Corporation</U>&rdquo;), does hereby certify as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"><U>FIRST</U>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
name of the Corporation is Apollo Medical Holdings, Inc. This Certificate of Amendment amends the Corporation&rsquo;s Restated
Certificate of Incorporation filed on January 16, 2015, and was duly adopted in accordance with the provisions of Section 242 of
the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"><U>SECOND</U>:&nbsp;&nbsp;&nbsp;&nbsp;That
Article IV of the Restated Certificate of Incorporation of the Corporation, as amended and/or restated to date, be amended and
restated in its entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&ldquo;The Corporation
shall have authority to issue an aggregate of 105,000,000 shares, of which 100,000,000 shares shall be Common Stock having a (1/10)
of one cent ($.001) par value each and 5,000,000 shares shall be Preferred Stock having a (1/10) of one cent ($.001) par value
each. Effective as of the date of the filing of this Certificate of Amendment to the Restated Certificate of Incorporation of the
Corporation (the &ldquo;Effective Time&rdquo;), a one-for-ten reverse stock split of the Corporation&rsquo;s Common Stock shall
become effective, pursuant to which each ten shares of Common Stock, par value $.001 per share, issued and outstanding or held
as treasury shares at the Effective Time, shall be reclassified and combined into one share of Common Stock, par value $.001 per
share, automatically and without any action by the holder thereof. No fractional shares of Common Stock shall be issued as a result
of such reclassification and combination and the Corporation shall pay cash in lieu of any fractional shares resulting from such
reclassification and combination.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"><U>THIRD</U>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Certificate of Amendment to the Restated Certificate of Incorporation has been duly adopted by the Board of Directors and stockholders
of the Corporation in accordance with Section 242 of the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">IN WITNESS WHEREOF,
the Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this 24th&nbsp;day of April,
2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">APOLLO MEDICAL HOLDINGS, INC.,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a Delaware corporation</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By: /s/ Warren Hosseinion</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 27pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Warren Hosseinion, M.D., Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v408340_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tex99-1logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt; text-transform: uppercase"><B>Apollo
Medical Holdings Announces reverse stock split</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt; text-transform: uppercase"><B>and
nasdaq listing submission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I>GLENDALE,
CA &minus; (PR Newswire) &ndash; April 24, 2015 &minus;</I></B> <B><U>Apollo Medical Holdings, Inc.</U></B> (&quot;ApolloMed&quot;)
(OTC-QB: AMEH),</FONT> an integrated patient&ndash;centered, physician-driven healthcare delivery company, today announced that
it has effected a one-for-ten (1-for-10) reverse stock split of its common stock. Beginning with the opening of trading on April
27, 2015, the Company&rsquo;s common stock will trade on a split-adjusted basis. The Company also announced that it has submitted
an initial listing application to the NASDAQ Stock Market to have its common stock approved for listing on the NASDAQ Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors approved the reverse
stock split on April 17, 2015, pursuant to authorization by shareholders at the Company&rsquo;s annual meeting held on September
30, 2014. The Board approved the stock split to support the NASDAQ Capital Market listing application. The Company cannot assure
that the listing will be approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the reverse stock split, each
ten shares of the Company&rsquo;s issued and outstanding common stock will be automatically converted into one issued and outstanding
share of the Company&rsquo;s common stock. The reverse stock split will affect all issued and outstanding shares of the Company&rsquo;s
common stock, as well as common stock underlying stock options, warrants, other common stock-based equity grants and any other
of the Company&rsquo;s securities converted into or exchangeable for shares of the Company&rsquo;s common stock, outstanding immediately
prior to the effectiveness of the reverse stock split. No fractional shares will be issued in connection with the reverse stock
split. Stockholders who would otherwise hold a fractional share of common stock will receive a cash payment in lieu of such fractional
share. The reverse stock split will not affect any stockholder&rsquo;s ownership percentage of the Company&rsquo;s common stock,
except to the limited extent that the reverse stock split would result in any fractional shares, which will be cashed out.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reverse stock split will reduce the
number of shares of the Company&rsquo;s issued and outstanding common stock from approximately 48.6 million to approximately 4.86
million. The reverse stock split does not have any effect on the Company&rsquo;s authorized capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s trading symbol of &ldquo;AMEH&rdquo;
will not change as a result of the reverse stock split, although it is expected that the letter &ldquo;D&rdquo; will be appended
to the Company&rsquo;s ticker for approximately 20 trading days following the effective date to indicate the completion of the
reverse stock split. In addition, the common stock will trade under a new CUSIP number, 03763A207.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stockholders holding shares through a brokerage
account will have their shares automatically adjusted to reflect the reverse stock split as of the effective date. Stockholders
with existing stock certificates who have questions may call the Company&rsquo;s transfer agent, OTC Stock Transfer, at 801-272-7272.
Stockholders with fractional shares will be cashed out directly by the Company without further action required by these stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: right; width: 100%"><i>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 2</i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Apollo Medical Holdings, Inc.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Headquartered in Glendale, California,
ApolloMed is a leading integrated patient-centered, physician-centric healthcare delivery company committed to providing exceptional
multi-disciplinary care in the communities it serves. ApolloMed is addressing the healthcare needs of its patients by leveraging
its integrated healthcare delivery platform comprised of six affiliated and complementary physician groups: ApolloMed Hospitalists,
ApolloMed ACO (Accountable Care Organization), Maverick Medical Group (Independent Physician Association), AKM Medical Group (IPA),
ApolloMed Care Clinics and Apollo Palliative Services. ApolloMed strives to improve medical outcomes with high-quality, cost-efficient
care. For more information, please visit <U>www.apollomed.net</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release may contain forward-looking
statements, including information about management's view of future expectations, plans and prospects for Apollo Medical Holdings,
Inc. (&ldquo;the Company&rdquo;).&nbsp; In particular, when used in the preceding discussion, the words &ldquo;predicts,&rdquo;
&quot;believes,&quot; &quot;expects,&quot; &quot;intends,&quot; &ldquo;seeks,&rdquo; &ldquo;estimates,&rdquo; &quot;plans,&quot;
&quot;anticipates,&quot; and similar conditional expressions or future or conditional verbs such as &ldquo;will,&rdquo; &ldquo;may,&rdquo;
&ldquo;might,&rdquo; &ldquo;should,&rdquo; &ldquo;would&rdquo; and &ldquo;could&rdquo; are intended to identify forward-looking
statements.&nbsp; In addition, our representatives may from time to time make oral forward-looking statements. Any such statements,
other than those of historical fact, about an action, event or development, are forward-looking statements.&nbsp;Such statements
are based on the current expectations and certain assumptions of the Company&rsquo;s management. Such statements are, therefore,
subject to a variety of known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company,
which could cause the actual results, performance or achievements of the Company, its subsidiaries and concepts to be materially
different than those that may be expressed or implied in such statements or anticipated on the basis of historical trends.&nbsp;
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company&rsquo;s
actual results, performance or achievements may vary materially from those described in the relevant forward-looking statement
as being expected, anticipated, intended, planned, believed, sought, estimated or projected. Unknown or unpredictable factors also
could have material adverse effects on the Company&rsquo;s future results.&nbsp; The forward-looking statements included herein
are made only as of the date hereof.&nbsp; The Company cannot guarantee future results, levels of activity, performance or achievements.&nbsp;
Accordingly, you should not place undue reliance on these forward-looking statements. The Company has submitted an initial listing
application to the Nasdaq Stock Market to have its common stock approved for listing on the Nasdaq Capital Market. At present,
the Company does not meet all of the initial listing requirements of the Nasdaq Capital Market and therefore the Company cannot
assure that the listing will be approved.&nbsp; Finally, the Company undertakes no obligation to update or revise these forward-looking
statements to reflect the impact of circumstances or events that arise after the date the forward-looking statement was made, except
as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for
by the Company. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and
risks discussed under Item 1A. &ldquo;Risk Factors&rdquo; of the Company&rsquo;s Annual Report on Form 10-K for the year ended
January 31, 2014 and in any of the Company&rsquo;s other subsequent Securities and Exchange Commission filings.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>RedChip Companies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Michael Sullivan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">800-733-2447 Ext. 115 or via email at <B>Michael@redchip.com</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tex99-1pg2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: right; width: 100%"><i>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 2</i></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tex99-1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tex99-1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1P$]`P$1``(1`0,1`?_$`,0```$#!`,!````````
M``````D`"`H"`P8'`00%"P$!``("`P$!``````````````8'!`4"`P@!"1``
M`0,#`P($`P4$`PP+`0```0(#!!$%!@`2!R$(,4$3"5$B%&%Q,B,*@4(5%I&A
M8K%20[,D-'6U=A<W.?#!T7*",V,E9288&1$``0,"!`,$!P0'!@<!`````0`"
M`Q$$(1(%!C%!!U%A<1.!D;'!(A0(H3)"%M'A4B,S8Q5B<J+"<W3QDM)#@R0T
M%__:``P#`0`"$0,1`#\`GY=:FE?$^>L-L#XY#(2<M5V845MP&@VKVJ\JGH1Y
MCX5.LUDK'G*,5Q=(UN!HL/R3,;'BL3ZR\3D14'HU"6XGZIUSR*4[BHI/]&LB
MWTBZU&7);!SG]@(I]JQ)KZ*W8Z4D4:*K637-C$^4&[8Q6.?WW.O]9KK?':5Y
M$VK\X/H_2M/^8H)#1N7[5LBRY;_$?3WE(*P*@$>)^'V:UEQI#X:U+J^A946H
MF3%H!]:SA#E0%`U!^W6K$.1QQ*SVS$BM%7O^S7+*OOG4Y*@J'QIK%DL_,X/<
M$^9`X@*XV:I\:]3KG#$869"23WKM:\2#,%7KM7)+1$M$2T1+1$M$2T1+1$M$
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MKBV2*9+:%/E(*J`)`I3XUZ=-:[5Y86M=E:U<M*M'O<"XDIQ6)Y*HR&8[3P6[
M0*2DJVT3_P"HI5$@_<3JL[P/ED.4845@6T,$#0YYH?!.4QO(6WT[5OME5`A:
M%+/R$'JH$`A5?OU&=4TZZ;&UT;#4GE3L6?#<63G%@>,P'8LW7)*4H6AE;Z5D
M44UM*0#3YCO*:#46F?=VYHX'UK)`B?\`=H1X*\7$@=4@&GQ\_P"C67;7!EH"
MOOR[2:T^Q76E;D`_:?#[]93N*^.8&'*."N:XKBEHB6B):(EHB6B):(EHB6B)
M:(EHB\VZW:W6:(J9<[C;[9'"DH^IN<QB#%"U'HE3[ZVVTDCPZZ(O'A9KB=RD
MHB6[)\;GREK"$1H=^M4N0\2FM&&(\MQU9Z?`'1%W+KE&.6)QMJ]7^RVAUY!6
MPU<[K!MZWDI_$6Q,?8W`5'AHBHM.4V"_//-62]V:[F*E"I:;7=85Q7&#Q4&%
M/?1//I;2X4$#<1X:(O9;>47`RL)#J4;W0DDI2E1(1M)`W5IU\-$78T1+1$M$
M2T1+1$M$2T1+1$M$2T1+1$M$2T1>+=;O;+4IM=SN,*VMK%&ESY<>(T\H$[D-
MJ><1O<2*&@^.O@MC,_,">RBZI[R"TB+I2`>]>.,[Q4I*QD-@+:7$MJ6+O!VI
M4M*U(0H^MT<6E"B!YA)/EK+^1-<M,:=@6@_,EIESYF9*\:G]"R(ES?+4$G_!
MA']J@HJFM79S.EN71R8-!P4BN`[ROA0@?<(Y+><SC'..FWE)@6ZW*NMQBI40
M7WY7I+AE2?`@)"MM=7ITYV]\]";T-SO)('P@TIWUYJK-S:C#;O\`+D>&FG:F
M96._[$%*5@;TB0MT*-&?3IMC_P#>-?#5W/MA;VYM",KW"@"KOYJ5\HGC)="T
MU)KA1.TX@Q[)N1+FS;[/&D+9B>FN=+0@J;C(5^\XNH32@\B3JL]PBQTQA=?O
M#*#@1B>ZBG>BW%[>T^18Y_\`=*SSN"S/DWMMM[3^+<+3.1+:60Y<\QGW"0BR
MVI5/WXS464I"01X`4U%]*CT'6Z--XR"1WX<HS#LYK+UJ7<UK$YT=K,YHYYL.
M"85&]S;G>%<3(3C6(1;:RY3^"BT-I:V@]5INOI?4`*_#U;J/'4Y9TBM[Z(/B
MU.1XIA^[!]'WE7<6^=3M+AS;R%T6%*EY_0GA<2>ZS8+O(CV_E?!7\08=4PTU
M=K1<7+W"4I:T(^H>:?CPOIH[==RJ5VI!\=0[7^D.JVK'264<UQ3A2,"O^)2G
M2NH<)>&3R-%>UY[/!%GP[-,8SVS1+]B]YMU^M4UI+T:?;WTO,.M*2%!:30*`
M(/F!JH]0T>XT>Y,%W$Z*8?A(H5:6C:XS48@Z$AQ/8:K,VBDH!32A)I3P^_6O
MJ'8MX+?.S5^+!RN:+BK:G6T`%2T@*6EL'QJM9HE/2O4G1%7N3UZ_A\?L\^NB
M*A3K:4!Q2P$$A.[RJHA('WDG1$B\T*?.GJHI^/S)!)2:>!`2=$5`DL$)(=31
M1"4]?$D5Z`]?#1%>J.G7Q-!]_P`*_'1%P%H/@I)_:-$5"GV4+0A3B0M:2I"?
M,I3U)Z>0T17=$5M;K;8*EK2D)!)J:=$I*S]IHD5T1`[_`%`&17.S^WUE%UQV
M^7"TR1D5J"9=I=6S+<:6'$*;;=0MM;52H=?'1%%A]E/.<ZNWN)]O]MNF89'-
MMLBZAA^W7"]3+BQ(!@R'/\JC/K"`NJ/MIHB)[^IRRK*<=Y4[;8^/9+>K%'F6
M7*'[G&MUPD1VYPBKM:6`IMI:`HC>?'1%E/Z7;*,DR&_]W@ON27F],L6OB]Z'
M$N<I]]B$)LS)$O%@.N.!+RTL@*(`KTT12]FGD^FMQ;:V4ME2=SM-Q;0*[_$D
MIZGXZ(KX<0I02%544!P"A_`HT"O"G4C1%P76PH(*TA15L":]2K;OVCXG;UT1
M4"2P>H=3U*DCKYI5M4*>/1736)-?6EM,RWGD:V>3[K3Q/@OH:X@N`^$+DR&`
MHH+J`H>*2:'KK)D>V$!TI#0>%5T"XA+_`"PX9^Q5^HW_`'P^.N3/C:'LQ:>"
MYND8P5<0`J?7:`*O430"I-?+XZQFWEJZ8P->TS`XCFNQH+VA[<6G@N#)8'BZ
MD=:>/GX_]>LP1O/`%8TEW;0FDKPT]Z2Y+"-N]U"=U-M3XUZ"GWZ^97=BRXV/
MF;GB!<VE<%PJ2P@54Z@"M.I\ZT_NZPY[ZTM79+B1K']A7)L,KC1K355^JW4#
M>*D%0^X$`GX>)UE,_>,\QF+#S7#([L5*I#"!53J$C[3KH9<P27!M&.!N6BI;
MS`[5U32,MVYYR&L)I4]O8N/JHX44^LC<$E1%>NT>)^X:Y&:)IHYP!7:]CHXC
M,\$1#B>20DL%.X.I*?B.HUD>5)6E#58\%Q!<U,#@ZG8@J^\O<[C%PWA,6RYS
MH"597DCKZ[:X4..JBV>,^VTZ4N-DIW#P^W5T=%=$TS7M1NHKYD<@8QI`<T._
M%CQ5/=6=9N]+@B=;%PC((<0XC'D#1`T@Y5D/\C9//_F+("\,RP69M+SNY+IL
M?(L8M)_/_`ML;C]J1KT._9.TQK\5H(;7&SE>1Y;>(?"`:>DT]*H!NY-:.D/N
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M2VHTA,E'HO-R&4O,+843N94TJJ25I534:L+RY@F$CLS2"*&M*%;^[<+F`P@@
MU'B@[=YW9!8[:F7RGQK;TQ$H6_+R/%8T<)B*2H+)N+"4&B2IRB2FGVUUZ+Z>
M]1)7W)T^]DJ\,P)=2OHIQ5+;KV:71BYC9@7'\/!"F9PUJJ3'CD*EJ4I]MY/R
MQMI.]L`CIKT+8ZRR_MP`X'#MJJGNM)?93XM(IW43K.UOG++.`\LBJ$^;<\)F
M7)N'>+;(6M:8,9U>Q*HS9)2A".GAJG-_[5BU'S)XV#YEPP<&U*LC:>O&Q<UA
M.`[Z*1QC5YAY%8[=?+>\E^#=(S<V(XD``L/H#C8(!/S)2>NO,]U;/M)W6\C2
MU[#0@X&JO33[QM_:MN6FH=WU7?N#H9C^H2TFBP?4>-$MT"E%P)_PBT!-0GI7
MXZQUFJ'-[E?O[\KXIRYEG`7:?'L.)6S"KM-LMXY#NI_B%RR=^&E/K*LJ$EG^
M#E#JB`O<[U&B(4LOW2O=)QJUVK.+KRGRM'Q.>](?@R9ENGRK1>9,@%J&Y)D+
M4PVW$9E4`!)W)&B(\WM"^]SGW<QR=9^W#N7M]B&8W>"^O%L]M-+0Q='X<=PN
M0Y\!9D>O._)4`YZ@J>E-$3A/?'[]>XKL@MG$<_M_N]GM,W*YTIO(7+Y8S>(L
MIF.B1Z2VZ2HHW(9;%?[6B('>$_J*^[>W<7\DP<@:Q[*^6KW<+=%XYNXL#ENM
MEFL2XSXOLA<),B4IV0U,#9;H02*Z(FDX_P"]A[B^(YDUE(YFGW!K^),/HLN0
MQ9-QPEZ8ZHN28CUK>=BF$E831`*E;=$4U?VP._FQ]_?;ZQR!+BQ;#R/CUV38
M^0,=AH#2HUT0EL1[HF*%%3-MN3F_TZ]#L/71$P'W>O>=G]FV4L\"]OUIM61\
MS/VSZV\7JX%,JUXON+GHQ9S`ZE]LHWK;*DDI(T11NW/=E]T7-+?<^1;3R]R5
M(Q.%(<5<+[B-KG)Q2V;5E4IM,-M;C:XL5>Y)/J``)T1$]]MSW^.5[YRWAG#?
M>$_;KWBV93H6.V+D6TQC#OEAO=Q=1&LTB_1%N/%;-U<<::55::)=W?9HB*Y^
MH/\`15[>&6/LN)=$C)K&OUD4V/!"4MI=;()3L4.HI4&M=$45/V1_^9/V_P#^
MGT?ZNF:(BC_JB_\`B[VR_P"S>7?XVU:(LH_2PEQ%^[NZE"D.67BSTP>GIMHF
MY)]6I:J^:%#:/,C1$^CW=/>CG=F-_5P?P#!L^4\R/01-N5[ND,7FU8B9!6W%
MM4VVI=9)FOJ0:**T[-P-#HBC>.>[#[I>8P[MR%9^4>2W,;BS&G)\ZRPIHQ:%
M.]1*WV6H[96VU;H(-5#?0!)T1$\]M?W^.6;SR]B7#W=RY9\CQC*YK-FM7)MK
M_+?QRX7"0(,&7<&U%?\`%%3[DXF.?G;]$.5Z[>I%(Q[^N=N0^#.&+7G7'#]L
MC7MS((\#ZZ<P+A%79WXS[B7V2A;25%]2$+!!Z5I]NIUT[V=I.[MQLAU,1`QM
MJUSVYJ8\!B%7/4/=<^V+2-\.:LE:T=E]R$'@_NH\^V>;<Y></V/+(:[3+;L\
M6+:51W/XVIUH1D/+#[I2WMW'PZTUZ"WST4VWIUC'(VZMV5QKY=,!Q'WN:H72
MNK%_<ZGY='NQ(_B?J6ILE]PKNSO%[5<)&>W?'U*D&1!C6BW/1;.B(553#FMJ
M=`6@)Z%7PU)]J=--BW>BM#A9/E:P"N0$D]O%;W<74G4[&Q,KO,&!_'3W)W.%
M>[7E%KX6R&)E-KM\[ER$XY%Q2[L,*>LDEIU`0B9,BIJIYZWN#>6]P+^ZE4TU
M7&Y/I^L[358[^UE9'97&=Q>V&C69:$"N;'-P"[MN=8;B[T]L1#G2M`'\6I/^
M%,ZN/N"]VJ[^Q-E\C3+9)B;9:+*W`>8QV9Z2C+^F2I;P]5+R54*J>!V^6IMI
M72O0;JT(A9!)(UM"X1UQ[>*BNY>I&J078QE#2?V_U(XG8-W87#N;PNZ)S!N`
MQGV)34L7%FUD%IZ`^RVIB8MOQ#?U+NT_:->=>H.T)-K:FZ/'R#B/ARBO9Q/+
M%7;TRW]-KEHV"5KBXX5+ZTQX\/0M==]_?^OM^NS7'7'4*-=>1)5O^ID2G@'(
M-K04_P"'2#T7UW"I&MMTTZ6:=OZ7YN_DCCA8X5+X\X('?4>"T76+J#J^T'?+
M::V4ROI3*_*145["A+*[W>]*\0;AE,?,\G1:0ZV[,?MMKDO6=A">KK<9U+FP
M-H5T5\->EM1V#TLT*!EC*=,-P`!BT-/#`TJJAV_OWJ5J\1N@W4?)%?Q$CUT3
MUNSKW*LUR[D'&^->;A:9=MR20W;;!E,57I.^LL_(BY)431:B.M2*'5*[]Z0:
M=I6F2;NT0QO#W!N6..GPD&IS5.&'8I1M+J;J^K;H9MO6Q,&`YB9)*T(X?#3W
MHLO<OSE8NW;B3)N2[PE#ST"*ZU9(2*%=PFNMUAQT"M5J=*?`>.J8VUME^X=6
MCL86DDG$AN:GH7HO>FX&:3MR6Y8X'*!AFIR\%&_RGW%^Z7);V_>K=G*\=M[R
MBNUVFSMKA)B545(#]M2MU4H;2`>HKKUQ#T@T2PT9C-09";H-%7.CH37TKS!H
MG4W4Y)7F`RY<QP$GZEC?/?=CG'<;QY@V)\D6Z&]DV+9'<[J+S"BKMHGQ9UMB
MPD+DL.*<4J4XMDA1KU&NKIKL2#;FYY9+5[76\["`UK*!M*GM-5K-X;PN=9VZ
M]UZUPFCE`JYU2<?!-D@@CCC*)-.JLTP)/TOP";;R/&(^\[Z_LU9TFFG\]0MI
MA_3)N7\Z#O4#9J0_)<LE</ZC%S_E3*:WE%X8CM/A)47P2V6Q7YDCIX?=K\[+
M>V+7-D`XT7Z$"8/S,'@@S^YA@#^06'"N6K(PI\8E*5:\L6P@K=;B2J&WN3J=
M1;XJ62E1Z4*AUU?W3+5!97DEI(<K7#,SD#^UCXJF-_Z89JN;QKV+3GMI6-O*
M>=$7*;_E(QRW29<J.FCC34X[3:'&R*_GL%*_4-?,:D?5+7'':\]O"X5E(8<:
M_"[BHGLC2S'N.U>[[K9`>"D8I:24I!1U14(K7Y=W15/OUY*9!''A@0O3ERSS
M&G+Q7#4=+((2@!/4TH?%1ZGJ==CF1N%`!58=O"]KZNX+HW2UP[S`F6RY1VY,
M.8PY'=8?3N:<0M)24J'2HZZ[+)SK"=MS"ZD@/$+(O;:*ZM_*>`4`GE[B3^3.
M2<FQOT4)CPY<F6E*$_(INY2#-AI%/*/&="!]@UZ?V-KAN(&.+B6D=H5&;KTE
ML<Q#0./8M=_R>-RCZ`JH`*HC\0'45ITZ$??J<ZG=031U-/6H=9V$[9*LKZD8
M7LER"5/XND8].E/ORL:NSP#CZMRDPII4N+&!/4-M(:('PUY4WZR!FXY/(`#2
MQI-.9/$^E7]LYDC-#8V2N;.[BG79-'FRK#=X$&6U$G7&%-APIC]"W$>E1ULL
MN[24[RTI=0!U.H:I2H;X_3@<GX_R#'Y$Y$[AN.T8A!SF3EE\1>;.^M5QM,V[
MN7&=!E2';N@['8ZRA5?ZM$3\?=F[N.Q*Q]D68]O]CSGC#-LX./6#&\:QK`EV
M:XW"RWBS^@TW-<?MWJ.6\,J;"RE77IUJ=$45?VOY+T+OU[=W8;[S*W,RBLN%
M*%-_*J*0\A*E5#B7%$E1'3<3HBD-?JC&4.8WVY@@?Y]=?,@$[IBNM"*U.B(<
M?Z>#MZP?F_O!R7)^1L6M646?CS`Y5SMMLO,,3(3%^;G6YN!/2PJC9?996L"H
M(()J-$3P_P!3+V\<>XG+X/YKPS&+-C4W(&+[9<N>LMN8MR+U](NW"T?6,14-
M1RJ*VXX$E*$JZFM=$6%?IC<[GV7F;N&PIEY0M^2X9:+X(:W3Z1=L#=T>]9"%
M$D.`R!U%/MT1`4[R^29?,G=;SOR7<)LF8]D_)MWFMO..J=<+<:8FT);2:T2A
M(@TH*#[-$7T*^QOM8XNQOL"XKX<5B]@?M68<5O-7]Y=HA.JN3F5PI4B2_+=4
MRIU;C:;A0$*!^7IHB^<KS987>*^=N4K-;$.0#QSRAEL"QI:JVY'38LCFHM;K
M/[P+$6.@H\:`#1%,B]TC+G\\]D/B7*Y;CSLZZX3Q4]/=?7O=D3CCMO$F0\H]
M5.NNI*B?,DZ(H\OLC_\`,G[?_P#3Z/\`5TS1$4?]47_Q=[9?]F\N_P`;:M$6
M1?I92I%V[S'22$HQ[BM8_L['LM6HBOQV_P!6B*.AWM<GR^9.[;GSE&9<'Y\C
M).1KLOZJ0Z5N*19Y0MNQ-*(2`B%0!*0.FB+Z$G8GVI\38IV#<;<01\9L$^RY
MIQJES)),BVQ77[E)S&WJD7!Y]QQM3KCS3$\I!W`C;TT1?.?YYQE_B'G[E[$;
M+%=AM\?<GY2WCB(^YOZ:)9LGF)MCL>@JGTF&4%/C2E=$4YGN6RQWD#VN.VW+
M);KCDV\X;QPJY27UE;\B<SB;*7W75GJIQ;Z"I7Q.K:Z-VLUWNV.&!Y:>)PK4
M*I>K&GPWNF1OER_!6E?8A\=@F`8SR?W-8-9,LALW2U-$W"9:9[6^'<WXNWT%
M/M@HW["JHH0->C^NEK?Z7MZ*X\TT##RIS"\_=.]M66H;D$9R'X^P_I1(/=[X
M]Q"S8+QS?[)CMJM=[8NQMHN-OB-Q'OH4AH)C*#(2VMM('[P)^W57]$+G4]3N
M;JS,[_*!:X`XBIK4^E6IU@V?866VO/:(VEK'#@1PI3FF0>V1QKBW(W<G;F\K
MMT.]0K)8[O<XUNN#(?BBXQ64.,R_1-$J<;6*BM1J==;MSZUMW;;(8C*V(`C-
MP!',#!5=TCVU:ZI>MA=D+`1RK[TZ;W@,(QG&Y?%=\LEHMMKN5U5<X$YV!$:B
MJ>B08X?BMN):2E!#;KA(Z5U'/INW/=:R9+)Y>Z-SJT+LWZU+NK.S[#3G1W#&
MQM%,<"/>O"]FQT(Y5YN6XJC4?CBSRMM=J=Z;\"I=/#>4CQUU?4;;"'5K>!K:
M.?+3AQJU;KI%%9VNC7-XTMSPPN=A@<*G!#5[E<QN6?<X<JY%,6[]1)RZ]V1M
MMY96I$&VRI$=@()H4MK$=)Z4U<NP=AP:'MN-]B]@EEMPXAK2""6UH<3C7[52
M^[-Z3[IUC/J$;S$V2@+W`B@-.0')2`N`^8>T;$^V_"N/).88/!ER<#CHO]JF
M""N9_&YUJ2[<DR?547$K,TJI7K\->.]Z:=OB^W;+<RMNVEL^5IR.IE::`C#@
M0O3^T-4V38;=CB;\H)#$2X9Q4DCGCQ4=*^_067EF\.8G-2];(N=JG8Y,M[H2
MVAAJZI4A<90*@E(;-!0TH=>U=.T%MUTQ;!J#VR3ACB0X8\.Q>6KNY<SJ([4;
M&-S(210MQ''A5&`]TOD&XW7A[MTBO.*0QE45[(I06JJ5R;-%MQ:<=3T"E-_5
MFGEUUYQZ+V%L_?5Q`P`M:'$#^Z>2OG?VH7$^TAYM0)`VM3QXC%:8]J+B*P<B
M<R91DN0VN!>X^%6A$J,FXL)D-1G;QZS4%Q#2_P`LJ9=CDIJ#J>_41NN^T*"/
M3K9[XFRL;6A`J#6HX5Q4&Z/;6LM4FD,X8X`NX@GWK/\`W<^&L3Q2\\<\@XY9
M[=8W<D5<+7,7;F!$^KGVUHRDR'&VR&]Z`XGP`\-:_P"GO<<FI2207LKI)H02
MW,:T810`'QJN_KAM:#1+5D5@QK(Y0TNR@TK7FA,0!_\`0LJC5Z#,\!5ZGVFP
M<E.5W5I_YXW??J]Y;Z+\^PG"G]+F''^=;E4G'82?D>5F-?ZC%R_E3*81F]W>
M1<I;2%H2XVXYM*A\I2">A3XUU^>5@!<QLB8*$#BOT#%V+>X>YPJ*G!-GR:XV
M:9#O=IRB(W=,<R*%(M>36YP%P/VQ^B75Q6^NV4T=I0KRIJ?VEA<0P17$#Q\U
M$<S3CZ10=JC^L1Q:F32C&GC7%:0[+>`;GP?W%7QS&WVK]Q3DN/2)-BOR5[)$
M$@E<6UW-EP^J[<OS"%N`!!H*#6)N[5YM0T;)(QS7YFD^A:W0]';9:BR7.TN!
M_P"",BIQ-=H\1UKM(']-*:I>[=.UO[H&M.2M)KV_B(]:L-R4K6MO<@J;("D!
MQ"E"M"-R?%/0^>L*V-\Y]7AX;X+D9(.3VU\5C6:9MC>"61_(,IND6T6F,4^M
M*D.H2$FH`2A)(4XI1(Z#KJ16]I/<DMA:YS@*X`E8%U?Q6C0\D.#C2@(P[T//
MGFTV[+LX_F&W+;4U?;7;I[+Q'^<PW(C*HCU/%`7'*2`=6_L^8Z;8QO=4BIPX
M4QQ&*K_66MU"4D8>*TB<.H2/2J!^]MZ?]*:F%UK(N6Y6U;XD+3V^GM@.9P!]
M:>YVD65=IM^9?(4(G2+<4NT^2L9$A"A0^*B'-49N\N.M.+G9B6-5F:`6G36Y
M&Y0''!;\Y@SF#Q;QIG?)E]=<39\'QV?E$QIL(!<CVF,[(<9<4ZE:4MND`*(H
M0//486Y7SA.Z+OL[M_<`YR;L<C-LN<C7G,$8_P`;<;8W<I-FM<4W*YJ@VR/"
M1!4P[+DK^51]=3J5$]!HB(QR)[!V2\#]IG('<OSURI]5GMKQ7^8G,$QIDM_P
M^?-8+<>/?KK<1,1*?8(2IXM*2*U'0C1$+3VPA3OI[;@557_.T<+"*KC@AI8'
MT[_5+Z2FA402`JHT12(_U1]/Y9[<JE*0+A<22I00``N6352NFB+0'Z8:^0V^
M<N=K,['6F?<,+:N5M=4D)]2WPI,-F2I((W*3Z[J!4=.NB)W'ZGNZQ%<+<"V<
MAH2;GEMT4AG<DN-,PS%3,<H/%#2EI!IYG1$.']-G:Y4SNXY)NS$H)C6WBK(H
MDB%M45/2)D)U#:%+!V(5&+?6OCNZ>&B(!')=NFVCDK.K3*0XQ/;SO*VT-N5*
MD[<HN4@J*O@A#@/VZ(OJ0=H3B3VQ\$(CI55/&>)*]5:DN(V?PZ,A_P#-3\A5
MT)IX@:(OF?\`>S>+?<^Z?N'N-OD)EP_][F='U&D%(46+U<;:ZWM/B424&I^&
MB*5I[A;3K/L/<,(=_'_)W&JE="@)"[+"4VG:JBC5L@@^%/OT1`8]D?\`YD_;
M_P#Z?1_JZ9HB*/\`JB_^+O;+_LWEW^-M6B+(OTM8<$[O/4I-&U8SQGL5N!W*
M0K+MXV^(IN'CXZ(HM/*MK?M'*O)4&Z1W(K\#/<N>^E=4$J4X<GN3[)*S1);?
M"P-$7U'NT$(5VT\!I6D)>8XOQ60$-+"D)2]9(J:DIZ.=304\"-$7S2^^*XQ;
MCW9=Q-UAONK0.2\]9<VTVM?3WZXQU,D%).]*T=1HBF)<B6R7;/:![76)SJWG
MG,=PB8DJ!31J7COKL)`/4I2VH"OGJY.B)F9NT30NRF..I[Q4"BJ?JT)3HC3&
M[+2OI3>_;(6M?=EB.[TPE%L?],A-"#1L5)/CTUZ`^H.>\U':32QY:&,-:XUJ
M0O/W1ZXG;N\"1]1G1)/>+33BK`"`$DY$NI\*J&SKJDOI\N+]VOOL8Y"V:3*,
MU,.?)7KUUBFGV>\1R!I#7>P)D?M&*1_^D'VU)_-3B%^<*QX*3]/^&GB2::NG
MZIIK&+8D%J(2;QKCF>#][`5PY55/?3YYYUAUL]]2P`UY&OZ$XWWG5!43ADE-
M%JF7Y5?()^B0`*?'IJN/I&;%+J+SY9;@.*F7U&7,VGZ:Q[7$D]BU=[.\5<WD
MSG6.A>PO<76MD^-2'+YLH#TIXZD?U25@W):N9P$HX<L`5%^@\EQJV@WKI'?N
M_(=5I_$,:CTH5W*_U$;E+DE#B@[)BYCEL1Q*04I2ZS?9J&"2JH4KT4@'XG5@
M=.M;UQNG-FU"25UN(Q0$`5:!A0T&%%'=P6FWYYC;6ELVWF!IF+JX\*\47KC;
MVFL4S?`,#S5SD:7;',IQBS9'=(K+*TJC.72VM27TI=>2H;6G'J'R'EJH]X=<
MM$@U&:"31YI+ADI8'-D&.4TS4[U*M!Z):]>P,OX=<M6VKFU\O(3Z*U5W_P#F
M9P99IK,*1W'V%^7:I*WFH$N[VM"PZF6R5-*0TIM_ZALC;0GQ/AK;V/5[69M,
M!9I.HG3WQN%*"@JTXUR\O%2B'IWI0NVZ?)>6C+]A!,I)`/=2O%=+W;,=AXSB
MG;5CMN=7<(UHL^2V^-(0DO-KB,L6="GE.(!3\P`/VZB?TV:A-J>_I9);>6,>
M5(3F'>%SZMP0Z7MMD3)HY,SF@93PI7OYJOV79C#68<T02Z1(E8]BAC(VDID)
MAR[JIXI<%4IV!P5!UO?JY?"W4[,-9_V6^U:?Z?FSR&X)?09C[ELWWF),9[%N
M%H]%5A95E"G6:;#MDV2*TVXFOXD)<ZU'0ZT'T_02QZC<7,51$(6C`<R3S[E)
M^N626""UD(,I:'5[J]B!E!<1_NWRANGYIR;`U^MY=(/([8%/'\!UZ+DCE_-L
M-SFP_I\PI_Y8"O/K!%^69+6@S?/1NK_XY1[U+AYF0]9[R)+8<+4E*U%00K8"
M>IJJE/'7AK1"VC",%[,O&/9.ZN.)3-\FO+A<<0"A`JIQR22%%E(\62SU*@[X
M^!\-6YIK&RPAHIP4=N[@QU[<5J"/R9DF%W!4W';X[;IID![T'U.*MY82:J'I
MIW%&[X"AUV7FA17T9BE;F8?'W+60ZHZ&X:^N(=W+9['N`\BX]%3%F6#'+ZIL
M;?JJSV5J^\%Q`U'9^EMQ=R@V+HXF4X$/*V5SN[Y9ASDG_E6`95[DO)0CNHLV
M&XQ&>HOU9?JS%2H;BDT"V@'RTX4]"`X%:W-AT:O?.8^ZFA=;C[S:/%?#L42N
MM_N^)L>?-7`_"FJ8QE_+_=WS5BF-9-EMWN]N-[@W>ZVX(<BVIBT6N0W-E,3D
MQ4-0&([\>.6D*70K60*DG6?N;:NE[1L1>V+&QS2$MJW,3PJ,#7"J[]"W#=ZY
M=/AF<YS&MKC3M[D9?(,:C7.Z2W(UO3'AL0&(41E"JIBP;;Z<*&RQ\QK5EM)H
M/+4"M;DV=HV*1P,A))([7$E3&.)TSJ\EY?\`)84VRV$5+BMM`.O4T\*5UBS:
MOD-`?8MK!IN=M2/:G5\88NG&<;7#]/:](>6\M1205!?5(-?':#J#ZU<_-WQF
M_L@>I2>RMQ;6XB`IC7UK6'>?@5QY2[4.X7CFTJ?1<LPXHRRPPEQZAX2)UL>;
M0IJE#O%.E.NM2LM?,'XESB7V^\_8!R//LMR=OO#W+EARA5NDNB.^O^4K^AYV
M%(CN*0M+D@1.B"-QW=-$4EGW$??CP'N8[9\BX'X(XWS-.6YW;+=_-5]O+5OD
M6VR6M!:=O#;<",E4]^,VE+FYT(4EM/4D4.B(&'MENQ;;WT]NJI+\:#$1GL-I
M"7'BU%9=?:VI0VY(6!68^O<A->I6`-$4B_\`5&K+>-=N2]ZFJ3[I\R6VW5&A
MF%24H=2IM1*?B.@ZZ(H\/MO=[V1^W_W`L<YVK'%91B4NUOXWGM@]>0)TO&KI
M(CS'!;9KKHL\:6'XK>T%0H=$6[_=A]SA/N+YSA#F/X7=>/./^.K?<&+/;KI*
MCR[P9%\5%=EKN)AN.L./)7#35:?EZ]#HB-;^F2[=<BM6+<[]Q&16A=NLV:.6
M["L-F2FE,/2G[6)G\=FL!T)*HTIN:R$J2-JB.AZ:(@,>[CVTY-VR][',-KEQ
M)<#`<PR1W(N/[TN&[Z:;1.*7B4.ALH>>7/\`5"DIJ=M.FB(R?:[[_P#QKQ+V
M2VWB;.L*R>5SM@&'SL8QR5"D)-FO3RF7TV>YN/!S\KT4NHW))!&WP&B*./P[
MQUFW=YW*6S#K%`>G9+RWR&;U=_I8CSS%O;OU^,V]J?#;:O2:C0)#JBM5`5IK
M4Z(II'O<8/&XR]J&W<=1?2]+`8N!8DMQL`(6G'[5%M;+ZB*)'K-1PH_:=$49
M/V2?D]R?M]W_`"[[^@HW?+O_`/;IGX:TW?LT1%%_5&+2GESMF*E)2!C.7J-2
M!1(=M(*C7R!(ZZ(LI_2PL-F^]XX4XL+=L?$[+S2ZA#39DY6-P"A0%Q*SN^P:
M(@R>[IVSY9VU][_*5JG6Q]&$YQ?GLHX_NLB&\B%-Q^XJ"Y#0DE`9=F19@>44
M@[DI()Z$:(C`=HWO^<;\2=D5LXLY%QG)+QSC@.(W7%<8F6UU*(5S?3]6+`Z^
M^M0"0P'6TD[@`$Z(HZ?$?'V;=W?<Q;\8M-HGS;SRGR(]>LE8AQWKB[;7\GO:
MW[LJ<8R7O2BQX$QQ?J*HC>/$Z(IY'N'8"SQ5V)<5<9QMIC\?L8=A[*VQ1+C6
M/8Z;6V\*``EU$8*/VDZN'HQ<,M]Q2O>:#R>VGXFJJ>JT;Y=)8Q@-23RJAK>V
M2H?_`*OQ7:05)MCY(!!-!Z533QIJ^NK]Y#=[3>UI!(9VCN[%Y]Z:6<]INELA
M!#<_8?>B5^\8L*XFX_43M"<B65*)``J&NI/@*ZJ#H/+':;H,[R!1S?>KLZOO
MENML^2P&I8>5?8F.^T=5'<W(0H'<G#+UN2>B@E;!VD@]0%`=-6A]1=Y!J>WF
M,:03YG:#[%6O1&SDT_5S.\$9A3@1P\4Y'WGJ*:X;2CREWQ*0.M:PT=!XUJ=1
M7Z:IH='O)7N(;C3C3VJ1]>;676;5D3,13O/L6N?9I.WEWFIHU"SQQ8P4_O`'
M($]=OXM9WU):A%J&HV]PT@@/-<1^SW+6]#=-ETO3+BW<#F?'3@1Q/>F7=\_#
M5WXBY_SN#.C/-V#(IK^6VF[%AUN/(DW"1]4Y%$A20VM27'B"*UU8/2G<6F[N
MTN.Q91CF1!GQN;R&4TH:XTJHKU`VU?:==NFB::9B<&NYX]B?1PM[G>-X5P%%
MQ#+K+=%YW8,9>L-F$0,F%+CB/]+;E;EUIZ2-A5]VH9OKH7Y6MNU."YM!9/>'
M9/C)[78]ZRML;^U33],^1>)O/#2`<K:4\"*H97$>-\@=P7.>/6*U.WB9.RW+
MD7"\+^H?6W:?\M$R4\XJ(K\J$D(*2HD(ZC4SU;<&W=L;&?;B(^:P$5:\<QV$
MIHK=:W)N9L`>6EV-7-P^P(YGNG\.S,A[?<9RBR0I-TF\?72WQTQH!HZBTS&4
MMW(N%1WA"?I$;B?VZHOH9O*RTK>!=*"#.UPK5HXGG56#U4V5J,FWO-SM<(LM
M`&NY(,?:!W,W#MCY(FY6S;EY#:)$27:,FL,9Q$53"'&]K#T9]U3275,E:CT4
M:'5U]8=H6W4BZA?;RPMD8QH#G$GF:_=*I[I]NV\V7')))',YI<?NM'^8+*.\
MONTN'=;DUFNT&PSL=Q/$X2V(4:8^V_\`4.J"B])4\RM;060JA%0:#69LG8;.
MF]L;*]G@GN9@'YHR0`TC!I#N87+<6^[C?SOGF1S,CB_=T>&DX8_A'#%-C@^G
M_NYR=[:=G\T8(CP_^(Y%=W?</'6TDU:V_,L0S-H+64<1SDA_0M<W3;G^A/?E
M=_'8>!_9D'O4U7/<,CYM8Y-M<6(TSYS%D)\4J'X03_>JKUUX&L;UUM)7\"]T
MW-BV0%PIF([T*?E;%LEPBZ2K;>H+K;(+AB7!EI2T2VTFBEK4D$`IJ/Z=7#MS
M4&SM;E-13N5?:O:F(&B:GD5V;ZD%EU(J5[DC>!Y^(J#JV+-K3&)#PHJ]N2Z.
M1:*R&Z-)]9QYU:$'<6FT=2?@*#4JTZ:$#,X%1[4)GOJP+!+)BN6\D7N%C6'6
M>XWZ^7-U+$9F#&=0S!:<5M+]S>VH05(ZFI)Z`:Q=>W7#I4)<210?V?>L?3M!
M??2@4!!\?<CY]I/:+#X$Q14JYI;N>=7^"TW?9:MQ#,<N"2F$FH"2EE_^L:\V
M[OZ@R:_,VW8[_P!6)U1P!)X<N5%<&V-G?TQSYG`5>VG/AQYIUO\`*;2UDK8]
M,A0)"1_V:A4NJE^%3]BFT6GB.F'P^E>K;L2AB5Z[S=$M'<V"/$U\0>FM;+<N
M<,%MXFM8V@P6?-[0@)2*)3\J?N'0'6$ZM:GBLD&H5B8A"V%!T!30ZNH4"4N-
M]0M"DBNX*!\//7%?4&/N/]COL5[B>09O(=PQJ[8;E5]N/\4O<G%IKR8-UN*U
M!2E/P!(#$)Q1`J4H3HBRG@/V7>QWMV@9>U8N/W+Y>\\Q^[8;>+UDT^?>9"+-
M?(CT&<FT"4])%H=7&E*`6UZ9"NM=$6$8?[#'87@.98SF^)XCED"^89?+;D=H
M<5DMTDH3<K5.:G1DJ,B>HN46T`*U`3T^&B(9GZH-OZ?$^W&*E?Y+UVN2RS)6
M5O;5_6[TB0HJ4DU53\6B)C_L$=M7"G=1<^Y3BSFO$(N48NK&H0BVV6GZ>7;7
M%^D/JK=.;V.MN)*JI4%"AT1')L'Z=GL%MUWCW-VVYC>;?!N(G-V:3>YS944.
M[TP9$E$T.2XB/P_,I51XZ(C8<><9X;Q-A5EP7CK&K9C&*6&,F):<=@-MLQVV
MT-H1N6I`&^71'51J2?$Z(M(]SG9SV[]X.)##N=L#AY@S;W`[`GT-MOUH=-"@
M1;NP6)*FFE]=OJ%/V:(A33OTX?89)E.)8?SN&)#HDM0DW:8XE#0.XLB29BE@
M4%*[JZ(B)]I?MR=J?9;%EO\`#/',2V9%)]-F9F5\K?[^X@!-50)4U4QZ"E13
MM(;4GI7XZ(MS=S_:WQ5W>\73.(>8($FZ89<)C,^9%MLQ^"_(>CC\OU7HKC+@
M57RK0?LT1,L[>?9C[)^V+E7&^9N*,,O]OS;%GOK+/+NN57JY-1G@A37RQY4]
M]"04.'IMIHBV[WB^VMVP=]-YQJ]\\8_>+Q<,,A3K5:W+;=[G;T-Q;FJ.IY)]
M"0P#UBIJ17PT1>SV<>W7VW]B$_/)_`]ENMI5R+&M+&1_Q.[S+FTINQJDKA@&
M9(?4DUF+^[1%L[N>[-^WGO"Q5.'\\X#;\Q@Q-KMMN"G'K;>;8^%;T&!>(*F9
MT=M2@-Z$N!+B>B@1HB$C,_3C=B:GWW(S^;VYIYU;B+?$N+KS3*5*)"$2)DL.
M*"0?,^6B(C_:/[<G:CV:H<E<,<=PX>3R&$-7#+;P\;K?Y"$@`E,J0Y)<CA1%
M=J"$CP'31$X3G3@?`>X'&XV'<@Q'KA96)PN28[%PEQ'"ZAEQNI,9QLUHYTUM
M]%UV;0KOSX"/,<VF-*<>]:C6=&CU>VR2#!OC[EH?ASL+X!X3S:%GV!6"9;K[
M`C/1F7Y5WN4JGJ*0:EN0^XVL41X'IJ5:WOW4M3L76=WE$9[`.'8H9HFQ;>QU
M#YF,"H-<2Y;@Y^[<^-.XZPQ,;Y#MLJ?!MSJ93*8TQZ)1SH0/R'D*\1J/;9W7
M<Z%>F:SRE]:XJ3;FVW%JFG^4X84(YK6W"'97PGP%E;V=X%8IUKOS\15K>>FW
M67+2J(XG82$O2'4A)!-.@UO=R[WO]?A^7O3&6@UJ,/0H_H>TH=':V6,8^)67
M<_\`:GQ+W*)Q]')=LD3TXU(>=M0CW.;;"VN0@)?(5">94]O0`**)`U@;=WC>
M;>+C9Y:N/.AQ6?JFV8M9(\T5`\1[%X/`G9_P_P!MUXO&0<;VJ9:[IDMK19KF
M[,N-PN"W(<68J8S13[KP24+H1X5TW3O&YW&6MO\`*0#RH.(H5ST3;,6AR@Q`
M9:XXGWK9_+W`W&'.5H39N2,7@Y#%0T4QI+BC'F,+((WM/H*'$FIKT/CK&VQN
M?4]H2>?H4@93&E`_VU6ZUW;UEKT1;*T%Q':?<F+J]J+MJCR?5BLY!#9=><]2
M,Y<)4\K0XI1#+;CS[JHR*=`4E/34TN.MV[M1/EWDGPGD8V`>NE56AZ86D5QF
M#0&^+DZW@WM:X>[=F'O]VV(MVFYOE3;]TGN*N%T=:<(+B1,?6^\VRZ0#M"@/
MLU%M8W7<ZZWY>\FC^7XY00,>_F5(X-J1[>C9J-BW_P!DN#:BKC3P."W_`'6S
M6N]6V?:9\")<+=/0MJX0[B`_'>;<3M<!;6%IZ@GRU%K41:=.VZMG!LH-005.
M=<@-YI1CN<6.:`>6"'IDWM;]L>1W9Z\BV76R_5O*<=@6Z:\F*M2EE:JI]=/R
MJ4KPIT&K'CZG;HM&#R7M^`#\(Y>A5UIG3;;E_;/%S%F!<?QN'L*SN;[>G;E*
MPF!Q^G#VV;/&F/W+UVY#S5PE2W([;*S*FH<#WH*0V*(W;:^777R#K%N+5)'Z
MC>OS2-:(Z.#6T`-:@#"N/%:1G271],E-KIK`V)[R[!SCCWDU*Q-KVQNV1JWS
M8:+!<_1GS;7<G[<;U/+!FVF#=[;$6E?U5`V(MZ>JBNTD@TJ!K4'J;J!U`7N9
MN8`M_#P)!]RD_P#^>VWR1M*"I(/%W('T\T2H(:%1NZDDUWFM2:FAK4==0AHH
M3EXJPR7T[EA>9P<$FPU1\T>Q]F$XRZE3MZG0H2D-FF]33\MUO:/B0>FMOIL^
MK02B336R.>#P:TN'I`!JM/>6^ERM(NW,`[W@>],-SG@/L[OTB0Y&Y@P?&7W2
MOUP.1,<=#9/XBEJ1>$`4/D=3R'<74EC*1VUR8O\`:O/VY%&9M&V2\_OIX0?]
M=H_S+75N[8>RF).8D9%W!<?WEMM0+<9[DK$+:7*$=/R[]55?VZSHMS]3FLI%
M:75/]H\_;D6"[0.GA/Q7%O7_`'+?^I/HX>QCMTQZ*+=Q!<^/[BZVA2796.9)
M8K]=UI(^8R)MOF292_E_OCT&H;N"_P!UWLIEUR.X97DZ)T;?40`M]I>G;5MZ
M#3I(7&O*5KO8XIP:&T``!1-$@`A9)H!T)-:DZA#8[82N<PCS3QQ]W)2S#*`/
MNJH!L"GR_;4@G]I)UW@-'#BN)IS2*6R.I%.G[U/N\]=@+N2ZW-C/$CUJL4`Z
M>&OAKS7-H:!1O!<*`-*^2@1UIU\OOU\7)=-E%O+KIC&.'@YND?3+;#A<'D^&
MSN)^Q6B*\6V3TW4(2L*HY11"A16X@U-!X5\-$5#K8HC:MRJ=NP)6KJH``%1!
M^9.T=1YZ(@+>]GVC\4=T5IX@A\G=U7"W;0C'I<Q<&;S!GN%84Q?0\J05HM)S
M"[VMN<XV\OKZ6XI(IHBU[[+'9CP[VNYIRG,X][O^"^Y67>[2RS=8W%O(N"9Q
M,M4=);++MP8Q:]721;X^T"A<2A)/GHBD6M!!9:Z@#8"G:0.G2H33]WP\.FB*
MJD;Y:^E^*B*E--_]CK^/[NNB*A349+>UY04C?NJ^YNZ_`*6?"GEHBO!*"BB2
M-AH1M-$@=*;2.FW^K1%;]-A:0$*2E(56K*]G6O4$H(KUT1<!N.K=Z:DBB_G]
M%S;\X\=^Q757QKUT15E+)<%2@.`U%"`OP/P-3T.B+D-IJA6Y7RH4D#>=I2=M
M2H5HHB@Z^6B*VXB,4/!PMA"@0[58"0/,DUHD]?'1%REIA`<.[<AQ04H+<*D)
M^5(2$A1HA-`*`:(JEI8#5'2@M4ZET@IIY5*S2FB*RVB"K>E@L!1`]0QUH2X$
M@BFY39W`5T1<J;B*4D%38<``%'`'"!X5-=QUB3Q6KY6NF($@X5-/LYKM8Z0-
M(97)SP5Q:&"?G*:FGBNE*>%*GIKNE;$YE)",E.U?&F0?=JK26X@4=JF]WG1P
M$_W:ZZ(8K1LF:$@R=QK]BYO?.64>#D\$G$0J++I9VD("@XM&P`$^F:*-!UK3
M7=(V$DF0BO>5TN-8\KOX:MK9@UJXMNJZ[-[P^7Y:'T05?+T^&NHQ6M<2*^*^
MQ%S?X7V8KL);9`51500`:N5'@*>?3PUP,-F3B6U_O(\N(.?@J5HB;`%EK;Y%
M2T_U$G69;!K/_GQ/=BD&=O\``J?#%5-H8`4&BDU`W%*P33RJ0:_=KG/5S:38
M-[\%R>Z0GXZU\%06HI)!4G=MH3Z@W;?B>M=1]UEH9FS.>SS?]0>RJYYYZ<#E
M\%U4QK8DU#C1HE0H9"5#::5)!7UI\?+6T\NUH*D4!PQ2Z?-)`YET*0GC44'K
M780U"2`$J;/7Y270HU^PE1ULBZ<\C2G8M?8QV\+"+(@M/&AS>Q<J:B%*@I:=
MI4%*)=`Z@B@)W=`3Y:UTL=LYI$A`;SQHLFWJPGR,37EBNM]/;*E7J-;=P.WZ
BA/IU`(`V[MOGK6_*:-3[[*5_;''UK-\V]KP=FIV&M%__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tex99-1pg2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tex99-1pg2.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.@`Z`P$1``(1`0,1`?_$`)X```$#!0$!````````
M``````@"!PD``0,$!@4*`0`!!0$!`0`````````````&``($!0<#`0@0``$#
M`P($!0($!`<```````$"`P01!08`$B$Q00=182(3"#(4<8%2(_"1L3.AP>&"
MHL(5$0`!`P,!!04&!@,````````!``(#$00%,2%!41(&87$B$P>!D:'!,A3P
ML='Q(S/A4L+_V@`,`P$``A$#$0`_`/OXTDEC<4E(]1`''B33AU.N4KR!RMU*
M\+0[5>=.NULM:`J?.C1=WJ0EUU*5KI^A%=RJ^0T^UMIJ$`$U3))HHAXB-%CA
MWNVW"BHSZ5[N`-*5\N/JUW?%)&/$#1<&7,<IHTKUDD<0.=?`ZXAW-M4EHH$O
M7J<JTDE6DDL1<-#Z>-.I\Z#IUU&=.6VYGIMK2B<YM$SO>3NM`[98VU<7$H=N
MMR>^PL\-3FTNRG$J)>6D<51V$H))I2M-$'3^*ES,C7T(8!4[Z5W*HR=[%:Q@
M\U'&OP03VON)<+Y,-QNLUR7*=>62MPEQ#8<.ZC84HA"4I(%!RUJS>G8HH0UC
M0#3AO0>;TW<NUY:WW[$1&(Y4&5,!2E4!2I)2I)6HD@CT5*P@=3H3S-I'9U%R
MT-/O_17MK*TO!LSYNW?L_5$=9KW]XD!:25JW%%?<!V`)/5H)_P`=`%S-9LDY
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M8EE[27'IEZO%G8NS=T64;1"0J2E9MC(<'!:$E0-#K'X^J;:?(M=EV.DMZZ`;
MNTZ(LO,#>?9DXI_ES4V5V?FHHLI[L_,+M5EMRLF29[D4"]PWT!Z++:9EVQYO
M=^W)MR'(WM2H;YXA0I0<*<-;CB,+Z:]10M%G;`W!;MI4T*R*[OO4'"79;=7'
M\0VT/#3BB]^/WSRO4JXP,5[W08[)E.MPX^96UA,=I$HK#8_]FWI]$=I:B*NH
M-/+6?]8>E9LA+D<03)%%XC&WQ.II0-&W?I2JT3I?K5U\^.SO_P"YYIS;@>TZ
M*4^-,8F,L28SJ'XTAM+K+S2T.,O-+&YMQIQ!*5H<2001TUC<M8GF)W]K=6[Q
MWC4+2FD/',T@MXC:%L[QXC^8U&\YW`ZKWF9Q'O7FSGD1V5.*(!*5;*_JZ$^0
MUWAC+[>@[_BD90R,@Z[5"M\^[1*M7</$^X\9EPVO*;(JQR9('I8NEG4\MF&L
M#Z'EPUE5">--?2'I/<6MQ9OQ4QI(7`@'>#O]]5A_7UO-;&/)-VL!=4^Y%Q\`
ML388[:R<[=0ERX9-<Y,:/(<`*V[=;E);;]I5/ID+))X_CX:!O5G(!V6&'C/@
MBVTXFORHB_T^Q\0QPR[QXI!0*01201R3SZBHIR/(CH=94M!0J_*7LY;^Y.!S
M)S$=L93BS2KI:98;2IUR,WN$J$^J@6^TZQ6@/TD5T7]&=3S].94.8?X9-A[R
MASJ/!6^3M'7$@_D:VGL&WYJ)(8"PI*2J/M"MH72IV5X$*Z\":>6OI#&9>*&9
MMU.:-N/F%CK<?)9-D\@5<-%*?\/\MN5PPJ;B%Z>,B5B+[,:VON**I#UGDU7%
M#A43N2P?2#SH-?.G7>&BQ68DR$?TSN)JM9Z4O9Y;003[#1%U[K/_`'_T_'RT
M`^/_`*]B+/M&?%<+G5Q5!98.X)WMN;#0\Q7B>/31%AX898S%)6A5=</=J[1!
MGW9M>+]R,7NV$9NR\_9[HI,QJXQ4)<N%AN[*5_9WN$DE.XQW2/=2DU6W7@='
M&"GGP-['=V8)EC^D'0C>'4^"%L_;6V4QSK&ZKY3M[=A%.W:GF^)..W+".SED
MPZ[7"TW239)UQC1+C97T/M7&`J9[D2X/LU#L:3(2O]UO;Z55T)];SON\V<L6
MO,SZ5&WE%=AILX*5TN&6^,;B@:0Q_3_M6M14]_8BG]Y2155.'%1V*2`*TYDT
M&A=TGCY6-<?QW(N8R4,K,YE>S]TS^8]V,"M^06_`'[U%FY5DK4V)"L<%8E2@
MRB(^J3)FH:*PQ%:!`)414ZN(<-D9&-OW,<VP8X5<0=>PZ::J`^^LYB^PE?5Q
M;7PG]T#KF#!3DA+3#;02\YL*&SM`2XHIJ"2"#36PW&0M<C:VD4;B(F4J0=NG
M'_""([0>;.6`EK=HKW[T0_QVQEVT7K(Y*$%##EOA1BK;0>^E]*R$FG+:3H'Z
M[NQ?Q1PN/ACT(U/>B+#,<QW-0!%Q1O\`1Y\AK-/N;GLTI^-J*^<KA^X%C?O=
MB>^TJ9D-2WHX2*EUL(.YA('%2B=7-C/Y%R&NV-)4#(AK(>;>`H\,LO#Q6ZVX
M'&EL+*7F"DH>;>1N2NJ5[5`M_P!#K<</]K':A[F![G`=NB`+N9TSZ,VM&O8F
M#N6:9#CTA4JQWF=:)*-ZR_!D.QW!7J4)(;*CPX\]7C<?C[X@3VXH3O`WJN=>
M/M:F(T?W[]R;7)_D#W<D1WHKG<7*&XI1M=";FZE2D*]))6E2N":U.K2TZ+Q,
M,@G-NTP\2!\U0WO462?&8'3D2G=4U^")SX3]EL@D2+OWURUJ<A^Z0I%HP]RX
MN//7*0U+6I%TO*B_^[M?:&UH&@(57PT$>I6:Q\#&=/8GD^WY0]_+N<:BG?0`
M]RN>A<3E9KEU[D`_R"2`YW!'NG"5#:E;;;KA"=J4)V[E'PX#KXZS)M^RTMFM
MA<21KV+21CQ&^0-%6N%*IU,1QMK'X"T);`?E.^^^H?\`%''].J:\NW73O$:@
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M*WVR+#BM1&&&68T5*&8L=ID-LL,-(2AEMMI)"$I;0D"@`'#66B2Y#G.NG\\C
MG$U["M%:^*1H\EO(P"E*46^F.V#4I0I70[`*?EIWFUV+VBS@`<NNDDKZ222K
MEI-37_2M=?,<^O+\M=@H$FHU2Q_://D?JY\OZZCR:C353(_H*2U_;Z_[OKZ:
BYW>FY/A^G?[5E3RU%B^G?KO71*'/79GU!)*U*356DDO_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
